| Literature DB >> 33299724 |
Michael Scheflan1, Tanir M Allweis1,2,3, Dafna Ben Yehuda3, Adi Maisel Lotan1,4,3.
Abstract
Prepectoral implant placement has many potential advantages in immediate breast reconstruction. Acellular dermal matrices (ADMs) are commonly used in these surgeries. ADM meshing may enhance integration, decrease seroma and infection rates, and reduce surgical costs.Entities:
Year: 2020 PMID: 33299724 PMCID: PMC7722619 DOI: 10.1097/GOX.0000000000003265
Source DB: PubMed Journal: Plast Reconstr Surg Glob Open ISSN: 2169-7574
Fig. 1.Illustration of the front and side view of prepectoral reconstruction with an implant and meshed acellular dermal matrix.
Fig. 2.Tissue expander wrapped in meshed ADM. A fully inflated (A, B) and fully deflated (C) tissue expander wrapped in 2:1 meshed SurgiMend. Note how the mesh maintains its shape, adaptation, and “pore” form regardless of inflation/deflation status. The acellular dermal matrix has been dipped in antibiotic solution containing betadine, hence its color.
Fig. 4.Implant wrapped in meshed ADM before placement. (A) Motiva Demi 425 cc implant (B, C) fully wrapped in a 2:1 meshed piece of 1-mm-thick SurgiMend and (D) then dipped in antibiotic solution containing betadine before insertion into the pocket.
Fig. 5.Immediate prepectoral breast reconstruction with 2:1 meshed ADM. A 35-year-old woman before (F–J) and 14 months after (A–E) unilateral nipple-sparing mastectomy through an inframammary fold incision on the right side, followed by immediate, prepectoral reconstruction with an Allergan FM 500 g implant wrapped in a 2:1 meshed piece of SurgiMend. The mastectomy weight was 535 g.
Baseline Demographics and Concurrent Treatments
| Variable | Prepectoral | Control | |
|---|---|---|---|
| Total patients, n | 49 | 77 | |
| Total breasts, n | 71 | 105 | |
| Age, years, mean (SD; range) Age, years, median (IQR) | 49.1 (9.4; 34–73) 48.8 (41.2–55.1) | 48.3 (9.6; 28–72) 47.0 (42.0–53.0) | 0.675 0.734 |
| BMI, kg/m2, mean (SD; range) BMI, kg/m2, median (IQR) | 24.7 (4.2; 18–39) 24.7 (22.4–27.3) | 23.5 (3.1; 18–35) 23.1 (21.2–25.0) | 0.091 0.086 |
| Smoking*, n (%) | 4 (8.2) | 8 (11.6) | 0.765 |
| Diabetes†, n (%) | 3 (6.1) | 3 (4.0) | 0.680 |
| Hypertension†, n (%) | 6 (12.2) | 8 (10.7) | 1.000 |
| Obesity†, n (%) | 4 (8.2) | 3 (4.0) | 0.423 |
| Chemotherapy‡, n (%) | 0.508 | ||
| None received | 31 (64.6) | 42 (60.9) | |
| Neoadjuvant | 10 (20.8) | 16 (23.2) | |
| Adjuvant | 7 (14.6) | 11 (15.9) | |
| Neoadjuvant and adjuvant | 0 (0.0) | 0 (0.0) | |
| Radiotherapy§, n (%) | 0.061 | ||
| None received | 49 (71.0) | 60 (62.5) | |
| Preoperative | 10 (14.5) | 8 (8.3) | |
| Postoperative | 10 (14.5) | 28 (29.2) | |
| Pre- and postoperative | 0 (0.0) | 0 (0.0) | |
| Reason for mastectomy‖, n (%) | 0.128 | ||
| Prophylactic | 26 (36.6) | 26 (24.8) | |
| Breast cancer | 45 (63.4) | 79 (75.2) |
Percentages are calculated per patient, unless otherwise stated.
*Data missing for 8 patients in the control group.
†Data missing for 2 patients in the control group; obesity was defined as BMI > 30 kg/m2.
‡Data are missing for 1 patient in the prepectoral group and 8 patients in the control group.
§Calculated per breast; data are missing for 2 breasts in the prepectoral group and 9 breasts in the control group.
‖Calculated per breast.
BMI, body mass index; IQR, interquartile range.
Reconstructive Procedure
| Variable | Prepectoral (N = 71 breasts) | Control (N = 105 breasts) | |
|---|---|---|---|
| Procedure, n (%) | 0.487 | ||
| 1 stage | 55 (77.5) | 87 (82.9) | |
| 2 stage (TE) | 16 (22.5) | 18 (17.1) | |
| Mastectomy weight, g, mean (SD; range) | 399 (201; 86–1000) | 394 (229; 65–1200) | 0.875 |
| Follow up, months, mean (SD) | 18.6 (13.0) | 21.3 (10.2) | 0.129 |
| TE reconstruction procedure* | |||
| Expander size, cm3, mean (SD) (N = 34) Expander size, cm3, median (IQR) (N = 34) | 420.3 (106.5) 450 (294–500) | 422.5 (109.7) 500 (338–500) | 0.953 0.929 |
| Intraoperative fill, cm3, mean (SD) (N = 19) Intraoperative fill, cm3, median (IQR) (N = 19) | 282.9 (57.9) 300 (240–350) | 204.2 (94.9) 180 (128–288) | 0.065 0.090 |
| Total expansion, cm3, mean (SD) (N = 21) Total expansion, cm3, median (IQR) (N = 21) | 424.6 (88.4) 475 (350–500) | 343.2 (158.4) 340 (295–500) | 0.225 0.322 |
| Time to drain removal, days, mean (SD; range) | 6.5 (3.0; 2–14) | 8.5 (3.9; 4–21) | <0.001 |
| Fat injection, n (%) | 9 (12.7) | 25 (23.8) | 0.101 |
| No. injections, mean (SD; range) (N = 34) | 1.2 (0.4; 1–2) | 1.6 (0.8; 1–4) | 0.097 |
*In breasts undergoing a 2-stage procedure.
IQR, interquartile range; TE, tissue expander.
Complications
| Variable | Prepectoral (N = 71 breasts) | Control (N = 105 breasts) | OR (95% CI) | |
|---|---|---|---|---|
| Total complications | 19 (26.8) | 31 (29.5) | 0.87 (0.45–1.71) | 0.690 |
| Minor | 11 (15.5) | 16 (15.2) | ||
| Major | 8 (11.3) | 15 (14.3) | ||
| No complication | 52 (73.2) | 74 (70.5) | ||
| Hematoma | 1 (1.4) | 0 (0.0) | — | 0.403 |
| Minor | 0 (0.0) | 0 (0.0) | ||
| Major | 1 (1.4) | 0 (0.0) | ||
| No complication | 70 (98.6) | 105 (100.0) | ||
| Seroma | 3 (4.2) | 6 (5.7) | 0.73 (0.18–3.01) | 0.660 |
| Minor | 3 (4.2) | 6 (5.7) | ||
| Major | 0 (0.0) | 0 (0.0) | ||
| No complication | 68 (95.8) | 99 (94.3) | ||
| Infection | 9 (12.7) | 12 (11.4) | 1.13 (0.45–2.83) | 0.802 |
| Minor | 5 (7.0) | 6 (5.7) | ||
| Major | 4 (5.6) | 6 (5.7) | ||
| No complication | 62 (87.3) | 93 (88.6) | ||
| Skin-flap necrosis | 6 (8.5) | 13 (12.4) | 0.65 (0.24–1.81) | 0.410 |
| Minor | 3 (4.2) | 4 (3.8) | ||
| Major | 3 (4.2) | 9 (8.6) | ||
| No complication | 65 (91.5) | 92 (87.6) | ||
| Capsular contracture | 6 (8.5) | 5 (4.8) | 1.85 (0.54–6.30) | 0.500 |
| Explantation | 2 (2.8) | 6 (5.7) | 0.48 (0.09–2.44) | 0.592 |
Data are represented as numbers (%).
CI, confidence interval; OR, odds ratio.
Complications in Non-irradiated and Irradiated Breasts
| Variable | Prepectoral | Control | OR (95% CI) |
|---|---|---|---|
| Non-irradiated | N = 49 breasts | N = 60 breasts | |
| Total complications | 10 (20.4) | 20 (33.3) | 0.51 (0.21–1.23) |
| Hematoma | 0 (0) | 0 (0) | – |
| Seroma | 3 (6.1) | 4 (6.7) | 0.91 (0.19–4.29) |
| Infection | 6 (12.2) | 8 (13.3) | 0.91 (0.29–2.82) |
| Skin-flap necrosis | 1 (2.0) | 8 (13.3) | 0.14 (0.02–1.12) |
| Capsular contracture | 0 (0.0) | 1 (1.7) | – |
| Explantation | 0 (0.0) | 1 (1.7) | – |
| Irradiated | N = 20 breasts | N = 36 breasts | |
| Total complications | 7 (35.0) | 9 (25.0) | 1.62 (0.49–5.30) |
| Hematoma | 1 (5.0) | 0 (0.0) | – |
| Seroma | 0 (0.0) | 1 (2.8) | – |
| Infection | 3 (15.0) | 3 (8.3) | 1.94 (0.35–10.67) |
| Skin-flap necrosis | 3 (15.0) | 5 (13.9) | 1.09 (0.23–5.15) |
| Capsular contracture | 6 (30.0) | 4 (11.1) | 3.43 (0.84–14.08) |
| Explantation | 2 (10.0) | 5 (13.9) | 0.69 (0.12–3.92) |
Data are represented as numbers (%). CI, confidence interval; OR, odds ratio.
Association between Radiation and Complications
| Variable | Non-irradiated (N = 109 breasts) | Irradiated (pre or post) (N = 56 breasts) | |
|---|---|---|---|
| Total complications | 30 (27.5) | 16 (28.6) | 1.000 |
| Hematoma | 0 (0.0) | 1 (1.8) | 0.339 |
| Seroma | 7 (6.4) | 1 (1.8) | 0.268 |
| Infection | 14 (12.8) | 6 (10.7) | 0.885 |
| Skin-flap necrosis | 9 (8.3) | 8 (14.3) | 0.349 |
| Capsular contracture | 1 (0.9) | 10 (17.9) | <0.001 |
| Explantation | 1 (0.9) | 7 (12.5) | 0.002 |
Data are represented as numbers (%).